Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Shelves Phase III Huntington's Candidate Tominersen

Follows Independent Committee Data Review

Executive Summary

Roche’s Phase III of tominersen in Huntington's disease has been stopped after an independent interim review, but with no new or emerging safety signals reported, analysts presume efficacy was the problem.

You may also be interested in...



Roche Jumps Back Into Huntington’s With Spark/NeuExcell Partnership

Deal Snapshot: Roche gene therapy subsidiary Spark gets option and will partner with start-up NeuExcell on a Huntington’s gene therapy that researchers say may regenerate functional neurons.

Early Data From Ionis/Biogen’s BIIB080 Keeps Tau Alzheimer’s Hopes Alive

While many other approaches have failed, Ionis and Biogen hope their novel oligonucleotide can stop toxic tau tangles forming in the brain.

Ionis Enlists Bicycle To Open Up New Antisense Targets In Bounce-Back Bid

Small-molecule drug delivery tech could help Ionis deliver its oligonucleotides where others cannot reach.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC144048

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel